PD-1/PD-L1抑制剂在肺癌合并肺结核患者中的应用与研究进展  

Progress in the treatment of PD-1/PD-L1 inhibitors in lung cancer complicated with pulmonary tuberculosis disease

在线阅读下载全文

作  者:范娜 蒋登蓉 王瑜 FAN Na;JIANG Dengrong;WANG Yu(Chonging Public Health Medical Center,Chongqing 400000,China;Department of Infectious Diseases,Chongqing Red Cross Hospital,Chongqing 400000,China;Hepatobiliary Pancreatic Tumor Center,Chongqing University Cancer Hospital,Chongqing 400000,China)

机构地区:[1]重庆市公共卫生医疗救治中心,重庆400000 [2]重庆市红十字会医院感染科,重庆400000 [3]重庆大学附属肿瘤医院肝胆胰肿瘤中心,重庆400000

出  处:《检验医学与临床》2025年第7期998-1002,共5页Laboratory Medicine and Clinic

基  金:重庆市教育委员会科学技术研究项目(KJQN202300133)。

摘  要:肺癌和肺结核是2种常见且严重危害健康的呼吸系统疾病,二者不仅在发病机制上存在一定的关联,在同一患者的临床表现中也常呈现出因果关系,针对肺癌合并肺结核患者,治疗需要综合考虑2种疾病的相互影响及个体化情况,权衡2种疾病治疗的优先级,同时减少药物的相互作用和不良反应。随着全球对肺癌和肺结核的关注增加,程序性死亡因子受体-1(PD-1)/程序性死亡因子配体-1(PD-L1)抑制剂在肺癌治疗中展现出显著效果,但其在肺癌合并肺结核患者中的应用仍需关注。尽管PD-1/PD-L1抑制剂在肺癌治疗中有效,但其在肺结核患者中的具体治疗效果和风险尚不明确。目前,对PD-1/PD-L1抑制剂在肺结核合并肺癌患者中的适用性和安全性了解不足,未来研究应积极探索免疫治疗与个性化管理,同时加强潜伏性结核分枝杆菌感染的筛查与免疫治疗前的风险评估,为患者安全与疗效提升提供指导。Lung cancer and pulmonary tuberculosis are two common and serious respiratory diseases that pose a serious threat to health.They not only have a certain correlation in their pathogenesis,but also often show a causal relationship in the clinical manifestations of the same patient.For patients with lung cancer complicated with pulmonary tuberculosis,treatment needs to comprehensively consider the mutual influence and personalized status of the two diseases,balance the priority of treatment for the two diseases,and reduce drug interactions and adverse reactions.With the increasing global attention on lung cancer and tuberculosis,programmed cell death factor receptor-1(PD-1)/programmed death factor ligand-1(PD-L1)inhibitors have shown significant efficacy in the treatment of lung cancer,but their application in patients with concomitant tuberculosis still needs attention.Although PD-1/PD-L1 inhibitors are effective in the treatment of lung cancer,their specific effects and risks in tuberculosis patients are still unclear.At present,there is insufficient understanding of the applicability and safety of PD-1/PD-L1 inhibitors in patients with tuberculosis and lung cancer.Future research should actively explore immunotherapy and personalized management,while strengthening latent tuberculosis screening and pre immunotherapy risk assessment to provide guidance for improving patient safety and efficacy.

关 键 词:程序性死亡因子受体-1 程序性死亡因子配体-1 抑制剂 肺癌 肺结核 

分 类 号:R734.2[医药卫生—肿瘤] R521[医药卫生—临床医学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象